CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 39 enrolled
Drug / intervention
Na-GST-1/Alhydrogel +5 morebiological
Likely dose
Albendazole 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03172975
NCT03172975Phase 2Completed
CompareCT.gov

Phase 2 Study to Assess the Safety, Efficacy and Immunogenicity of Na-GST-1/Alhydrogel Co-administered With Different Toll-Like Receptor Agonists in Hookworm- Naïve Adults

Baylor College of Medicine·interventional·Posted Jun 1, 2017·Updated Mar 12, 2026

In Brief

A Phase 2 clinical trial evaluating Na-GST-1/Alhydrogel, Na-GST-1/Alhydrogel + CPG 10104, and 4 other interventions for Hookworm Infections. Completed, enrolled 39 participants across 1 site.

Detailed Summary

This study evaluates the efficacy, safety and immunogenicity of different formulations of the Na-GST-1 hookworm vaccine using a controlled human hookworm infection model in healthy, hookworm-naive adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHookworm Infections
CountriesUnited States
CollaboratorsGeorge Washington University, National Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 1, 2017
Enrollment StartMar 1, 2018
Primary CompletionDec 31, 2024
Study CompletionJan 30, 2025
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 9.1 years ago

Interventions

Na-GST-1/Alhydrogelbiological

Recombinant Necator americanus Glutathione-S Transferase adjuvanted with Alhydrogel

Na-GST-1/Alhydrogel + CPG 10104biological

Recombinant Necator americanus Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with CPG 10104, a synthetic oligodeoxynucleotide

Na-GST-1/Alhydrogel + GLA-AFbiological

Recombinant Necator americanus Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with an aqueous formulation of Glucopyranosyl-Lipid A (GLA-AF)

Placebobiological

Physiological sterile saline solution

Albendazoledrug

Treatment with 3 daily oral doses of 400 mg albendazole at end of study.

Necator americanus Larval Inoculumother

50 infectious Necator americanus larvae applied via dermal application (challenge infection).